Based in Denmark, Sanos is a global Contract Research Organization providing services to pharma, biotech and research organizations to help plan and conduct clinical trials.
Sanos Group consists of a CRO specialized in osteoarthritis (“OA”) and a Site Management Organization (“SMO”) with a broader indication range focusing on lifestyle and age-related diseases.
Sanos’ scientific leadership in OA, a highly prevalent disease that currently affects more than 240 million people worldwide, together with its strong network of key opinion leaders and its integrated value chain with three owned research clinics in Denmark, makes it a preferred strategic partner for OA clinical trials, states Investcorp. Investcorp plans to support Sanos’ efforts to capitalize on its multiple market opportunities by further increasing its penetration in OA while looking to grow into clinical trials for other therapeutic areas and expanding its research clinics network into new geographies, the company states.
“Sanos has built its business through a deep commitment to conducting clinical research that delivers scientific excellence and high-quality data to bring effective medical treatments to patients in need. Thanks to its global resources and experience growing international businesses, Investcorp is an ideal partner to help us improve more patients’ lives by expanding into new markets and therapeutic areas while continuing to add value at every phase of clinical trials,” says Jeppe Ragnar Andersen, CEO of Sanos.
Investcorp’s 11th investment in the healthcare sector and the third in Europe
Investcorp has an established history of investing in the healthcare sector globally. The acquisition of Sanos is Investcorp’s 11th investment in the healthcare sector and the third in Europe, following its acquisition of a majority stake in Cambio Healthcare Systems, which operates in the Electronic Health Records market, and Acura, a network dedicated to providing accessible and high quality dental care across Germany.